Biotinylated Human IL-33 Protein, His,Avitag? (MALS verified)
分子別名（Synonym）
IL33, DV27, C9ORF26, IL1F11, NFHEV, DKFZp586H0523, DVS27, NFEHEV, RP11-575C20.2
表達區(qū)間及表達系統(tǒng)（Source）
Biotinylated Human IL-33, His,Avitag (IL3-H82H5) is expressed from human 293 cells (HEK293). It contains AA His 109 - Thr 270 (Accession # O95760-1).
Predicted N-terminus: His
蛋白結構（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 21.9 kDa. The protein migrates as 28-33 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
白細胞介素33（IL33）又稱C9orf26、DKFZp586H0523、DVS27、NF-HEV、NFEHEV、RP11-575C20.2，是屬于IL-1超家族的細胞因子。IL-33能誘導輔助T細胞、肥大細胞、嗜酸性粒細胞和嗜堿性粒細胞產生2型細胞因子。其通過與ST2受體（即IL1RL1）及IL-1受體輔助蛋白（IL1RAP）相互作用，激活NF-κB和MAP激酶信號通路中的細胞內分子，促使極化Th2細胞產生2型細胞因子（如IL-5和IL-13），從而介導生物學效應。在體內環(huán)境中，IL-33可誘導IL-4、IL-5和IL-13的表達，并導致黏膜器官出現(xiàn)嚴重病理變化。
關鍵字： IL-33;IL-33蛋白;IL-33重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。